← Back to Search

Device

tDCS for ADHD

N/A
Recruiting
Led By Joan Camprodon, MD, PHD, MPH
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male and female outpatients 18-65 years of age
A diagnosis of ADD/ADHD or meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 1 - week 8 of study
Awards & highlights

Study Summary

This trial is testing whether a home-based tDCS device can help improve symptoms of ADHD and cognitive control over a four week period. They are also testing whether there is a dose-dependent response to tDCS.

Who is the study for?
This trial is for adults aged 18-65 with a diagnosis of ADHD according to DSM-5 criteria. It's not suitable for pregnant or nursing women, individuals with epilepsy, metallic head/neck implants, brain stimulators, pacemakers, active substance dependence (except tobacco), or severe psychiatric disorders like bipolar disorder and schizophrenia.Check my eligibility
What is being tested?
The study tests if home-based tDCS can reduce ADHD symptoms and improve cognitive control over four weeks. Participants will receive either a low dose (1 mA), high dose (2 mA) of stimulation, or a sham treatment to compare effectiveness.See study design
What are the potential side effects?
tDCS may cause mild side effects such as tingling at the electrode site, fatigue, headache, nausea or itching under the electrodes during application. Serious side effects are rare but could include seizures in susceptible individuals.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 65 years old.
Select...
I have been diagnosed with ADD/ADHD.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 1 - week 8 of study
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 1 - week 8 of study for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adult ADHD Self-Report Scale
Global Assessment of Functioning (GAF) Scale
P300 Amplitude during Erickson Flanker Task

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: 2mA transcranial direct current stimulationExperimental Treatment1 Intervention
Group II: 1mA transcranial direct current stimulationExperimental Treatment1 Intervention
Group III: Sham transcranial direct current stimulationPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,928 Previous Clinical Trials
13,198,295 Total Patients Enrolled
59 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
8,479 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Joan Camprodon, MD, PHD, MPHPrincipal InvestigatorMGB: Division of Neuropsychiatry and Neuromodulation

Media Library

2 mA transcranial direct current stimulation (tDCS) (Device) Clinical Trial Eligibility Overview. Trial Name: NCT05354232 — N/A
Attention Deficit Hyperactivity Disorder (ADHD) Research Study Groups: 2mA transcranial direct current stimulation, 1mA transcranial direct current stimulation, Sham transcranial direct current stimulation
Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trial 2023: 2 mA transcranial direct current stimulation (tDCS) Highlights & Side Effects. Trial Name: NCT05354232 — N/A
2 mA transcranial direct current stimulation (tDCS) (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05354232 — N/A
Attention Deficit Hyperactivity Disorder (ADHD) Patient Testimony for trial: Trial Name: NCT05354232 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research include geriatric participants?

"This research project is seeking participants aged 18 to 65."

Answered by AI

Are there any available slots for participants in this research trial?

"Affirmative. The details found on clinicaltrials.gov suggest that this research project is presently recruiting individuals for the trial, which was first made public on July 1st 2022 and has been refreshed as recently as July 21st 2022. Sixty people are required to be enrolled at one medical site."

Answered by AI

Could I potentially join this clinical trial?

"This clinical trial is seeking 60 male and female outpatients between the ages of 18-65 to participate. All potential enrollees must have been diagnosed with Attention Deficit Hyperactivity Disorder - Inattentive Type, or meet the criteria outlined in DSM-5 for such a diagnosis."

Answered by AI

How many participants are accepted in this clinical trial?

"Affirmative, clinicaltrials.gov reports that this examination is currently enrolling participants. The trial was first advertised on July 1st 2022 and has since had its details amended. 60 volunteers are required from a single medical facility."

Answered by AI

Who else is applying?

What state do they live in?
New York
Maryland
Massachusetts
Other
How old are they?
18 - 65
What site did they apply to?
Massachusetts General Hospital
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
1
2
0
3+

Why did patients apply to this trial?

I've tried meds and now would like to try your trial. I have tried Methlypenidate atomoxotine and lisdexamfetamine.
PatientReceived 2+ prior treatments
I want to learn more about my disease and by contributing, we will be able to gain more insight.
PatientReceived 1 prior treatment
It's important to have an impact in Adhd research during this condition there is many complications to manage relationship with everyone and everything.
PatientReceived no prior treatments
I've tried ADHD medications along with therapy and while I have received some benefit, I still have major struggles with executive function, motivation, distractibility, among others.
PatientReceived 1 prior treatment

What questions have other patients asked about this trial?

~0 spots leftby May 2024